Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31479756 | 0.92 | HCRTR1 (0.36) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31479296 | 0.87 | HCRTR1 (0.36) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31478986 | 0.86 | MEN1 (0.36) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31479799 | 0.85 | MEN1 (0.36) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31479586 | 0.85 | ENPP2 (0.39) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31479662 | 0.85 | HCRTR1 (0.35) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31479594 | 0.83 | MEN1 (0.41) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31479832 | 0.83 | HCRTR1 (0.40) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31479417 | 0.83 | HCRTR1 (0.37) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31478993 | 0.82 | ENPP2 (0.37) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |